Finally, CDRI-85/287 arrested tumor growth in a MDA-MB 231 xenograft model of human estrogen receptor-negative breast cancer, showing that the potent effect of this compound could also be manifested in vivo, with concomitant inhibition of EGFR pathway in the treated tumors. The gene discussed is EGFR; the disease is neoplasm.